Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Avid has previously developed a florbetapir-PET scan binary read methodology and training program, which was successfully applied in studies 18F-AV-45-A08(NCT01565369), 18F-AV-45-A09(NCT01565382) and 18F-AV-45-A16(NCT01447719). In these previous studies, training was conducted in-person. Study 18F-AV-45-PT01 will evaluate an automated version of this training program suitable for web-based distribution. Nuclear medicine physicians will complete the automated training program then read the florbetapir-PET images from 151 subjects with repeat readings of 33 randomly selected images. Readers will rate each case as either positive for significant tracer accumulation in cortical gray matter or negative for significant tracer accumulation in cortical gray matter. The inter-rater reliability, sensitivity and specificity of the readers will be evaluated.
The primary image set for determination of inter-reader agreement is comprised of images from 119 subjects from two previous clinical studies (A07[NCT00857415]/A16[NCT01447719] and A05[NCT00702143]). This included all 59 subjects who came to autopsy in Study A07(NCT00857415) and it's follow-up study, A16(NCT01447719), and a set of 60 cases randomly selected from Study A05(NCT00702143) subjects, including 20 cognitively-normal controls, 20 with mild cognitive impairment) MCI, 20 with AD.
Subsequently, the protocol was amended to include all remaining A05(NCT00702143) MCI patients that were not used in the training program (n=32); 13 of these 32 scans presented for repeat reading (to increase the number of A05 MCI cases with repeated reads to 20). This increased the number of unique cases in the validation dataset to 151 scans with 33 scans repeated yielding a total of 184 scans reviewed by the readers.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Eligibility for subjects scans to be used in this study is determined by subject's eligibility/enrollment in Study A05 (NCT00702143) or A07 (NCT00857415).
Alzheimer's disease (AD) group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- Have probable AD per National Institute of Neurological and Communication Disorders and Stroke (NINCDS) criteria
- Mini mental state exam (MMSE) score between 10 and 24 inclusive
Mild cognitive impairment group key eligibility criteria (from Study A05[NCT00702143):
- Male or female at least 50 years of age
- Complaints of memory or cognitive decline corroborated by an informant
- Clinical dementia rating of 0.5
- No obvious cause for cognitive impairment (eg, head trauma or stroke)
- Cognitive impairment onset within the past year
- MMSE score greater than 24
Cognitively normal volunteer group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- MMSE score greater than or equal to 29 and cognitively normal by informant report and psychometric test battery at screening
Autopsy cohort key eligibility criteria (from Study A07[NCT00857415]):
- Male or female 18 years or older
- Projected life expectancy of less than 6 months
- Consent to brain donation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Seul
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Inter-rater Reliability
Délai: Scan acquired 50-60 min post-injection
|
Measure of agreement among five readers using a binary read method (amyloid positive/negative) calculated using Fleiss' kappa.
All scans were read in a blinded fashion without access to clinical information.
|
Scan acquired 50-60 min post-injection
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
Délai: at autopsy, within 2 years of scan
|
Calculated as the percent of true positives which are correctly identified
|
at autopsy, within 2 years of scan
|
|
Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
Délai: at autopsy, within 2 years of scan
|
Calculated as the percent of true negatives which are correctly identified
|
at autopsy, within 2 years of scan
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Median Sensitivity and Specificity vs. CERAD Diagnosis
Délai: Baseline scan
|
Median sensitivity and specificity for 5 independent readers to detect moderate to frequent amyloid plaques (per CERAD criteria).
|
Baseline scan
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 18F-AV-45-PT01
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .